SoftOx Solutions AS — Capital/Financing Update 2022

Jan 17, 2022

SoftOx Solutions AS: Cancellation of subsequent offering

SoftOx Solutions AS: Cancellation of subsequent offering

Reference is made to the stock exchange announcement by SoftOx Solutions AS (the "Company") published on 15 December 2021 regarding the successfully completed private placement of approximately NOK 50 million through the issue of new shares in the Company at a subscription price of NOK 55 per share (the "Private Placement"). In the announcement it was expressed that the Company would consider undertaking a subsequent offering of up to 218,000 new shares at the same subscription price as in the Private Placement, depending on the development of the price of the shares in the Company after completion of the Private Placement.

The board of directors has resolved not to proceed with the Subsequent Offering. Following announcement of the Private Placement, the Company’s shares have traded around or below the subscription price in the Private Placement. Accordingly, any shareholder wishing to reduce the dilutive effect of the Private Placement have had the opportunity to purchase shares in the Company in the market at prices similar to or below what would have been the subscription price in the Subsequent Offering.

For further information, please contact:

CEO Geir Almås of SoftOx Solutions AS, or

CFO Kristine Rød of SoftOx Solutions AS

Mail: ir@soft-ox.com

Mobile: (+47) 948 59 599

About SoftOx Solutions AS

SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian BioTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com